Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study.

BACKGROUND: Microelimination of hepatitis C virus (HCV) among people living with human immunodeficiency virus (HIV) may be feasible in Australia, given unrestricted access to direct-acting antiviral (DAA) therapy from 2016. Our aim was to evaluate progress towards elimination goals within HIV/HCV-coinfected adults in Australia following universal DAA access. METHODS: The CEASE prospective cohort study enrolled adults with HIV/HCV, irrespective of viremic status, from 14 primary and tertiary clinics in Australia. Annual and cumulative HCV treatment uptake, outcome, and HCV RNA prevalence were evaluated, with follow-up through May 2018 (median follow-up, 2.63 years). Factors associated with DAA uptake were analyzed. RESULTS: Between July 2014 and March 2017, 402 participants who were HIV/HCV antibody positive were enrolled (95% male [80% gay and bisexual men,], 13% cirrhosis, 80% history of injecting drug use [39% currently injecting]). Following universal DAA access, annual HCV treatment uptake in those eligible increased from 7% and 11% per year in 2014 and 2015, respectively, to 80% in 2016. By 2018, cumulative HCV treatment uptake in those ever eligible for treatment was 91% (336/371). HCV viremic prevalence declined from 82% (95% CI, 78-86%) in 2014 to 8% (95% CI, 6-12%) in 2018. Reinfection was reported in only 5 participants for a reinfection incidence of 0.81 per 100 person-years (95% CI, 0.34-1.94). CONCLUSIONS: High uptake and effectiveness of unrestricted DAA therapy in Australia have permitted rapid treatment scale-up, with a dramatic reduction in HCV infection burden and low reinfection rate among people living with HIV, suggesting that microelimination is feasible. CLINICAL TRIALS REGISTRATION: NCT02102451.

Reliability and Diagnostic Thresholds for Ultrasound Measurements of Dermal Thickness in Breast Lymphedema.

BACKGROUND: Lymphedema of the breast, secondary to treatment for breast cancer, is difficult to assess due to the shape of the breast and the nature of the tissue. Ultrasound measurement of dermal thickness has been previously used to assess breast swelling; however, the reliability of the measurements, or what should be considered an abnormal thickness, is currently known. METHODS AND RESULTS: Thirty-eight women with breast edema were recruited and underwent assessment using ultrasound. During the assessment, the four quadrants (superior, inferior, medial, and lateral) of the affected and unaffected breasts were imaged three times each. Dermal thickness was then measured by two assessors, on two occasions for each captured image. The interimage, intrarater, and inter-rater reliability was all found to be excellent (Cronbach's alpha = 0.995; ICC(3,1) = 0.962 and 0.851; and ICC(2,1) = 0.977, respectively). A dermal thickness of >1.6 mm in the superior and lateral quadrants and 2.0 mm in the medial and inferior quadrants was determined, by receiver-operating characteristics curve analysis, as the optimal diagnostic threshold to detect breast edema. CONCLUSION: Dermal thickness measurements can be reliably completed on breasts with edema secondary to breast cancer. Future study is needed to determine the utility of the dermal thickness thresholds established as well as to investigate changes in dermal thickness as a response to treatment of breast edema.